AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.57+0.20 (+0.19%) ▲|ACN180.39+2.49 (+1.40%) ▲|ADBE245.07-3.76 (-1.51%) ▼|AMAT457.40+3.39 (+0.75%) ▲|AMD503.03-0.57 (-0.11%) ▼|AMGN384.30+1.83 (+0.48%) ▲|AMT175.60+2.61 (+1.51%) ▲|AMZN256.21+4.32 (+1.72%) ▲|AVGO363.48+2.65 (+0.73%) ▲|AXP324.91+4.18 (+1.30%) ▲|BA208.54+3.69 (+1.80%) ▲|BAC63.78+1.21 (+1.93%) ▲|BKNG174.28+0.37 (+0.21%) ▲|BLK1,080.99+18.45 (+1.74%) ▲|BMY64.05+0.31 (+0.48%) ▲|BNY164.33+1.72 (+1.05%) ▲|BRK-B509.04+2.03 (+0.40%) ▲|C140.92+2.39 (+1.72%) ▲|CAT817.78+12.78 (+1.59%) ▲|CL88.34+0.45 (+0.51%) ▲|CMCSA25.31+0.14 (+0.54%) ▲|COF210.58+3.49 (+1.69%) ▲|COP135.82-1.23 (-0.90%) ▼|COST905.11+2.73 (+0.30%) ▲|CRM247.90+4.80 (+1.97%) ▲|CSCO109.40+1.96 (+1.82%) ▲|CVS96.04+0.75 (+0.79%) ▲|CVX213.29+0.53 (+0.25%) ▲|DE689.56+11.61 (+1.71%) ▲|DHR202.36+1.88 (+0.94%) ▲|DIS106.49+0.64 (+0.61%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.20+1.82 (+1.23%) ▲|FDX314.52+2.70 (+0.86%) ▲|GD355.64+1.35 (+0.38%) ▲|GE328.12+4.00 (+1.23%) ▲|GEV950.00+26.61 (+2.88%) ▲|GILD145.64+0.83 (+0.57%) ▲|GM87.15+1.05 (+1.22%) ▲|GOOG337.20+6.81 (+2.06%) ▲|GOOGL339.35+6.75 (+2.03%) ▲|GS1,037.83+18.10 (+1.77%) ▲|HD311.00+5.30 (+1.73%) ▲|HON203.43+1.25 (+0.62%) ▲|IBM236.56+2.49 (+1.06%) ▲|INTC101.41+1.09 (+1.08%) ▲|INTU318.36+5.59 (+1.79%) ▲|ISRG372.53+12.07 (+3.35%) ▲|JNJ269.03+2.69 (+1.01%) ▲|JPM359.72+6.23 (+1.76%) ▲|KO88.40+0.57 (+0.65%) ▲|LIN464.16+2.54 (+0.55%) ▲|LLY1,127.01+3.74 (+0.33%) ▲|LMT529.21-0.77 (-0.15%) ▼|LOW199.46+2.86 (+1.46%) ▲|LRCX299.94+1.93 (+0.65%) ▲|MA568.38+2.96 (+0.52%) ▲|MCD253.82+0.79 (+0.31%) ▲|MDLZ62.69+0.22 (+0.35%) ▲|MDT92.25+0.63 (+0.69%) ▲|META659.47+15.09 (+2.34%) ▲|MMM163.29+0.43 (+0.26%) ▲|MO69.49+0.73 (+1.06%) ▲|MRK145.06+0.34 (+0.23%) ▲|MS216.60+3.89 (+1.83%) ▲|MSFT496.81+4.37 (+0.89%) ▲|MU978.18+0.77 (+0.08%) ▲|NEE82.95+0.49 (+0.59%) ▲|NFLX76.94+0.93 (+1.22%) ▲|NKE36.94+0.33 (+0.89%) ▲|NOW133.76+2.58 (+1.97%) ▲|NVDA219.49+1.13 (+0.52%) ▲|ORCL156.50+3.33 (+2.17%) ▲|PEP136.99+0.34 (+0.25%) ▲|PFE27.66+0.02 (+0.07%) ▲|PG144.83+1.83 (+1.28%) ▲|PLTR166.88+1.02 (+0.61%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.57+0.20 (+0.19%) ▲|ACN180.39+2.49 (+1.40%) ▲|ADBE245.07-3.76 (-1.51%) ▼|AMAT457.40+3.39 (+0.75%) ▲|AMD503.03-0.57 (-0.11%) ▼|AMGN384.30+1.83 (+0.48%) ▲|AMT175.60+2.61 (+1.51%) ▲|AMZN256.21+4.32 (+1.72%) ▲|AVGO363.48+2.65 (+0.73%) ▲|AXP324.91+4.18 (+1.30%) ▲|BA208.54+3.69 (+1.80%) ▲|BAC63.78+1.21 (+1.93%) ▲|BKNG174.28+0.37 (+0.21%) ▲|BLK1,080.99+18.45 (+1.74%) ▲|BMY64.05+0.31 (+0.48%) ▲|BNY164.33+1.72 (+1.05%) ▲|BRK-B509.04+2.03 (+0.40%) ▲|C140.92+2.39 (+1.72%) ▲|CAT817.78+12.78 (+1.59%) ▲|CL88.34+0.45 (+0.51%) ▲|CMCSA25.31+0.14 (+0.54%) ▲|COF210.58+3.49 (+1.69%) ▲|COP135.82-1.23 (-0.90%) ▼|COST905.11+2.73 (+0.30%) ▲|CRM247.90+4.80 (+1.97%) ▲|CSCO109.40+1.96 (+1.82%) ▲|CVS96.04+0.75 (+0.79%) ▲|CVX213.29+0.53 (+0.25%) ▲|DE689.56+11.61 (+1.71%) ▲|DHR202.36+1.88 (+0.94%) ▲|DIS106.49+0.64 (+0.61%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.20+1.82 (+1.23%) ▲|FDX314.52+2.70 (+0.86%) ▲|GD355.64+1.35 (+0.38%) ▲|GE328.12+4.00 (+1.23%) ▲|GEV950.00+26.61 (+2.88%) ▲|GILD145.64+0.83 (+0.57%) ▲|GM87.15+1.05 (+1.22%) ▲|GOOG337.20+6.81 (+2.06%) ▲|GOOGL339.35+6.75 (+2.03%) ▲|GS1,037.83+18.10 (+1.77%) ▲|HD311.00+5.30 (+1.73%) ▲|HON203.43+1.25 (+0.62%) ▲|IBM236.56+2.49 (+1.06%) ▲|INTC101.41+1.09 (+1.08%) ▲|INTU318.36+5.59 (+1.79%) ▲|ISRG372.53+12.07 (+3.35%) ▲|JNJ269.03+2.69 (+1.01%) ▲|JPM359.72+6.23 (+1.76%) ▲|KO88.40+0.57 (+0.65%) ▲|LIN464.16+2.54 (+0.55%) ▲|LLY1,127.01+3.74 (+0.33%) ▲|LMT529.21-0.77 (-0.15%) ▼|LOW199.46+2.86 (+1.46%) ▲|LRCX299.94+1.93 (+0.65%) ▲|MA568.38+2.96 (+0.52%) ▲|MCD253.82+0.79 (+0.31%) ▲|MDLZ62.69+0.22 (+0.35%) ▲|MDT92.25+0.63 (+0.69%) ▲|META659.47+15.09 (+2.34%) ▲|MMM163.29+0.43 (+0.26%) ▲|MO69.49+0.73 (+1.06%) ▲|MRK145.06+0.34 (+0.23%) ▲|MS216.60+3.89 (+1.83%) ▲|MSFT496.81+4.37 (+0.89%) ▲|MU978.18+0.77 (+0.08%) ▲|NEE82.95+0.49 (+0.59%) ▲|NFLX76.94+0.93 (+1.22%) ▲|NKE36.94+0.33 (+0.89%) ▲|NOW133.76+2.58 (+1.97%) ▲|NVDA219.49+1.13 (+0.52%) ▲|ORCL156.50+3.33 (+2.17%) ▲|PEP136.99+0.34 (+0.25%) ▲|PFE27.66+0.02 (+0.07%) ▲|PG144.83+1.83 (+1.28%) ▲|PLTR166.88+1.02 (+0.61%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|
21.9 C
New York
Friday, September 11, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Parker opening kicks off Kaiser Permanente’s new chapter in Colorado

New buildings opening, additional Westminster and Rock Creek investments announced DENVER, July 8, 2025 /PRNewswire/ -- Kaiser Permanente is announcing a major expansion of its medical...

The Aesthetic Society Unveils New, Easier Access to On-Demand Learning Through The Aesthetic Society Academy

Netflix-style interface enhances the learning experience for Aesthetic Society and AlliedPro members—designed to advance education and support professional growth. GARDEN GROVE, Calif., July 8, 2025...

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Shareholders of Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – HIMS

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.

Ingenio Care Closes Pre-Seed Funding to Launch AI-Enabled, Patient-Centric Digital Health Network — Pilots Now Open for IPAs, Employers, and Health Plans

Ingenio Care, Inc. has finished pre-seed round funding and is looking to launch pilot programs to put their patient-first app into motion.

New Fat Burner for Women Launched Over the Counter – PhenQ Medically Accredited Fat Burning Supplement

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide. 
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers